Cuban Academy of Sciences develops vaccines for the treatment of non-small cell lung cancer- Vaxira and CIMAvax. This latest type of vaccine that can treat non-small cell lung cancer (NSCLC) has undergone phase 3 clinical validation and has a good effect on non-small cell lung cancer. It has now entered clinical applications in Kuba va Peru. Ushbu hayajonli tadqiqot natijalari AQShning sobiq prezidentiga imkon berdi Barak Obama tashrif buyurganidan keyin 55 yillik savdo taqiqini bekor qilish Kuba, and introduced the latest anti-cancer technology to the United States in 2015. The US Food and Drug Administration (FDA) has approved the United States to conduct a clinical trial of a lung cancer vaccine developed in Cuba, which can stimulate the lung cancer patient’s own immune system.
CIMAvax nima?
CIMAvax-EGF is a o'pka saratoni treatment that was developed in Cuba. It is a type of immunoterapiya that harnesses the body’s immune system to fight lung cancer. In 2017, Roswell Park initiated a clinical trial involving CIMAvax. Trial is a Phase I/II study of CIMAvax-EGF in combination with the anti-PD1 checkpoint inhibitor nivolumab (Opdivo®) in patients previously treated for advanced kichik hujayrali o'pka saratoni (NSCLC).
CIMAvax qanday ishlaydi?
Developed by researchers at the Center for Molecular Immunology (CIM) in Havana, Cuba, CIMAvax-EGF blocks a type of protein — epidermal growth factor (EGF) — that cancer cells need to grow. It does not kill cells directly, cancerous cells or otherwise, but “starves” them by preventing EGF from attaching to its proper receptor (EGFR) on the cell. This connection is required for the cell to grow and proliferate. Without it, the cancer cell does not multiply, and dies. CIMAvax blocks EGF by manipulating the patient’s immune response.
CIMAvax tarkibidagi "tashuvchi oqsil" immunitet tizimini neytrallash uchun EGF oqsiliga qarshi antitellar ishlab chiqarishni boshlaydi. Bu qonda aylanadigan EGFni kamaytiradi va saraton hujayralarini o'sish va omon qolish uchun muhim kalitdan mahrum qiladi.
More than 5,000 lung cancer patients have been treated with this unique immunotherapy, and several international studies have indicated prolonged shish stabilization and improved overall survival and quality of life for patients receiving CIMAvax. CIMAvax is an approved treatment for lung cancer in Argentina, Bosnia and Herzegovina, Colombia, Cuba, Kazakhstan, Paraguay and Peru.
Vaxira nima?
Vaxira® is a therapeutic vaccine for the treatment of non-small cell lung cancer (NSCLC). It is composed of Racotumomab and aluminum hydroxide adjuvant.
Rakotumomab - bu antidiotypik monoklonal antikor, bu bemorlarda o'simta hujayralarida mavjud bo'lgan o'ziga xos glikolillangan gangliozidlarga (NeuGcGM3) qarshi kuchli immun reaktsiyasini keltirib chiqaradi. Vaxira® eng yaxshi qo'llab-quvvatlovchi parvarish bilan taqqoslaganda NSCLC bemorlarining takroriy yoki rivojlangan bosqichlarida (IIIB / IV) omon qolish darajasini oshiradi. Vaxira® yaxshi muhosaba qilinadi va uning xavfsizlik profilini qabul qilish mumkin. Ko'pincha noxush hodisalar lokalizatsiya qilinadi (administratsiya joyida), engil va vaqtinchalik.
Kasalligi avj olgandan keyin Vaxira® bilan immunizatsiya qilingan bemorlar ham umumiy omon qolish holatini yaxshilashgan.
Formulyatsiya: VAXIRA® ning har bir flakonida quyidagilar mavjud: mAb Racotumomab 1.00 mg, alyuminiy gidroksidi [Al (OH) 3] 5.00 mg, tris (gidroksimetil) aminometan 12.14 mg, natriy xlorid 3.40 mg, ukol uchun suv qs 1.0 ml. Vaxira® antidiotypik monoklonal antikor Racotumomab va alyuminiy gidroksidi (AH) dan tashkil topgan immunoterapiya vositasidir, bu keng tarqalgan yordamchi vosita. AH antikorlar ishlab chiqarishni kuchaytiradi, ammo immunogen ham, hapten ham emas. U antigen sekin chiqariladigan in'ektsiya joyidagi omborxona sifatida o'zini tutadi va shu bilan birga antitel ishlab chiqaradigan plazma hujayralari kabi immunokompetent hujayralarni o'ziga jalb qiladigan granulomalar hosil bo'lishiga olib keladi. AH to'g'ridan-to'g'ri monotsitlarni T hujayralarini faollashtira oladigan proinflamatuar sitokinlarni ishlab chiqarishni rag'batlantirishi mumkin va B hujayralari reaktsiyasini ham rag'batlantirishi mumkin.
Hindistonda CIMAvax va Vaxira-ni qanday sotib olish mumkin?
CIMAvax and Vaxira at present are not available in Hindiston. These vaccines need to be ordered for personalized treatment. To order the medicine please WhatsApp patient details to + 91 96 1588 1588.
